Core Insights - The company reported a revenue of 1.019 billion yuan for the first three quarters of 2025, representing a year-on-year decline of 2% [1] - The net profit attributable to shareholders reached 220 million yuan, showing a year-on-year increase of 1.45% [1] - The net profit excluding non-recurring items was 173 million yuan, reflecting a year-on-year growth of 3.10% [1] - The basic earnings per share stood at 1.25 yuan [1]

Financial Performance - The company's revenue for the third quarter was ¥364,685,045.87, a decrease of 1.55% compared to the same period last year[4]. - Total profit for the quarter reached ¥92,352,352.05, representing an increase of 28.42% year-over-year[4]. - Net profit attributable to shareholders was ¥83,590,556.58, up 18.52% from the previous year[4]. - The net profit after deducting non-recurring gains and losses was ¥69,186,088.86, reflecting a growth of 27.85% year-over-year[4]. - Total operating revenue for the first three quarters of 2025 was CNY 1,019,133,615.33, a decrease of 2.8% compared to CNY 1,039,937,156.56 in the same period of 2024[21]. - Net profit for the first three quarters of 2025 was CNY 220,162,482.66, slightly up from CNY 217,023,597.92 in 2024, representing a growth of 1.0%[23]. - The company reported a basic earnings per share of CNY 1.25 for the first three quarters of 2025, compared to CNY 1.24 in 2024[23]. Assets and Liabilities - The company's total assets increased by 4.67% to ¥3,558,922,033.10 compared to the end of the previous year[5]. - Current assets reached RMB 2,075,169,166.49, compared to RMB 1,928,705,677.43 at the end of 2024, indicating an increase of about 7.63%[17]. - Total liabilities stood at RMB 1,186,539,861.36, compared to RMB 1,189,252,367.98 at the end of 2024, showing a slight decrease of about 0.23%[18]. - The total liabilities decreased slightly to CNY 692,940,971.40 from CNY 702,205,924.57 year-over-year[22]. - The total equity attributable to shareholders increased to CNY 2,865,981,061.70, up from CNY 2,697,921,576.03, reflecting a growth of 6.2%[22]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥218,818,190.70, showing a significant increase of 49.21%[10]. - Operating cash flow for the first three quarters of 2025 increased to CNY 218,818,190.70, compared to CNY 146,646,770.03 in the same period of 2024, marking a significant increase of 49.2%[26]. - The company recorded a total cash inflow from operating activities of CNY 1,159,913,582.80, compared to CNY 1,027,032,791.52 in the previous year[26]. - The net cash flow from investing activities was -$586.19 million, compared to -$156.23 million in the previous period, indicating a significant increase in cash outflow[27]. - The net cash flow from financing activities was -$37.61 million, an improvement from -$175.47 million in the previous period[27]. - The company experienced a net decrease in cash and cash equivalents of -$405.18 million, compared to -$185.30 million in the previous period[27]. Research and Development - Research and development expenses totaled ¥62,188,527.85, a decrease of 25.99% compared to the same period last year[5]. - Research and development expenses for the first three quarters of 2025 were CNY 183,301,396.13, a slight decrease from CNY 188,129,351.01 in 2024[22]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,482[13]. - The top shareholder, Wang Ying, holds 34.89% of the shares, totaling 61,593,000 shares[13]. - The company has not reported any significant changes in the participation of major shareholders in margin financing or securities lending activities[15]. Other Information - The company recognized non-recurring gains totaling ¥14,404,467.72 for the quarter[8]. - The company will not apply new accounting standards starting from 2025[28].

证券代码：688513 证券简称：苑东生物 公告编号：2025-076 成都苑东生物制药股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 成都苑东生物制药股份有限公司（以下简称"公司"）即将于 2025 年 10 月 28 日披露公司 2025 年第三季度报告，为加强与投资者的深入交流，使投资者更加 全面、深入地了解公司 2025 年第三季度的经营成果、财务指标等情况，公司计 划于 2025 年 10 月 31 日（星期五）上午 11:00-12:00 举行 2025 年第三季度业绩 说明会，就投资者关心的问题进行交流。 1 会议召开时间：2025 年 10 月 31 日（星期五）上午 11:00-12:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 24 日（星 ...

Company Overview - Yuandong Biopharmaceutical Co., Ltd. is located in Chengdu, Sichuan Province, established on June 1, 2009, and listed on September 2, 2020. The company specializes in the research, production, and sales of chemical raw materials and chemical drug formulations [1] - The revenue composition of the company includes 78.75% from formulation sales, 9.22% from raw material sales, 6.79% from technical services and transfers, 4.01% from CMO/CDMO, and 1.22% from other sources [1] Stock Performance - On October 23, Yuandong Biopharmaceutical's stock fell by 5.05%, trading at 50.42 yuan per share, with a total transaction volume of 48.39 million yuan and a turnover rate of 0.53%. The total market capitalization is 8.901 billion yuan [1] Fund Holdings - Huatai-PB Fund has a significant holding in Yuandong Biopharmaceutical, with the Huatai-PB Value Growth Mixed A Fund (460005) holding 418,200 shares, representing 2.45% of the fund's net value, making it the third-largest holding [2] - The fund has experienced a floating loss of approximately 1.1208 million yuan as of the latest data [2] Fund Manager Information - The fund manager of Huatai-PB Value Growth Mixed A Fund is Fang Wei, who has been in the position for 11 years and 66 days. The total asset size of the fund is 2.127 billion yuan [3] - During Fang Wei's tenure, the best fund return was 260.51%, while the worst return was -17.22% [3]

Core Insights - The article highlights the journey of Yuandong Biopharmaceuticals and its chairman Wang Ying, focusing on the company's resilience and strategic decisions in the pharmaceutical industry [1][2]. Company Overview - Yuandong Biopharmaceuticals has transitioned from a focus on high-end generic drugs to innovative drug development, achieving significant progress in its drug pipeline [2][5]. - The company has successfully industrialized over 70 high-end chemical drugs, including 9 domestic first-generic products and 61 that have passed consistency evaluations [4]. Strategic Decisions - The company initially chose to develop high-end generic drugs to avoid competition in the low-end market, which has proven effective over the years [3]. - Yuandong Biopharmaceuticals has maintained a stable growth trajectory despite industry pressures, with a reported net profit of 137 million yuan in the first half of 2025, showing year-on-year growth after excluding stock incentive costs [3]. Research and Development - Since 2012, the company has invested in R&D, with a focus on innovative drugs, which it views as essential for future growth [5][6]. - The company employs a strategy of "using generics to promote innovation," allowing cash flow from generics to support the development of innovative drugs [7]. Clinical Progress - As of the first half of 2025, the company has made substantial advancements in its innovative drug pipeline, with over 80 projects under research, of which 24.4% are innovative drug projects [7]. - Notable achievements include the completion of clinical trials for several drugs, indicating a shift from initial development to broader market readiness [7]. Future Aspirations - Wang Ying expresses a vision for significant growth in both profits and revenue over the next decade, reflecting the company's long-term strategic goals [8].

Core Viewpoint - Yuan Dong Biotech (688513.SH) announced that its subsidiary Chengdu Shuo De Pharmaceutical Co., Ltd. has received the drug registration certificate for "Elaidomide Tablets" from the National Medical Products Administration, indicating a significant regulatory milestone for the company [1] Group 1 - The active ingredient of Elaidomide Tablets is Elaidomide, which is indicated for the treatment of active rheumatoid arthritis [1] - Elaidomide Tablets are classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2024) [1]

Core Viewpoint - Yuan Dong Biotech (688513.SH) has received a drug registration certificate for Elamomide tablets, indicating a significant regulatory approval for the company’s product aimed at treating active rheumatoid arthritis [1] Group 1: Company Information - The drug Elamomide, developed by the company's wholly-owned subsidiary Chengdu Shuo De Pharmaceutical Co., Ltd., has been approved by the National Medical Products Administration (NMPA) [1] - Elamomide tablets are classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog for 2024 [1]

Core Viewpoint - Yuan Dong Biotech (688513) announced the approval of its subsidiary Chengdu Shuo De Pharmaceutical Co., Ltd. for the drug registration certificate of Elamomab tablets by the National Medical Products Administration [1] Company Summary - The active ingredient of Elamomab tablets is Elamomab, which is indicated for the treatment of active rheumatoid arthritis [1] - Elamomab tablets are classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2024) [1]

Group 1 - The core point of the article is that Chengdu Yuandong Biopharmaceutical Co., Ltd. has received a drug registration certificate from the National Medical Products Administration for its product "Elamomab Tablets" [1] Group 2 - Chengdu Yuandong Biopharmaceutical's wholly-owned subsidiary, Chengdu Shuo De Pharmaceutical Co., Ltd., is responsible for the newly approved product [1]

Core Viewpoint - Yuan Dong Biotech (688513.SH) has received approval from the National Medical Products Administration for its drug, Elamomab Tablets, which is indicated for active rheumatoid arthritis and is classified as a Category B drug in the 2024 National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog [1] Group 1 - The company’s wholly-owned subsidiary, Chengdu Shuo De Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Elamomab Tablets [1] - Elamomab, the active ingredient in the tablets, is specifically aimed at treating active rheumatoid arthritis [1] - The drug is included in the 2024 National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog as a Category B product [1]